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Abstract 
Background: The availability of tests to predict the risk of developing chronic 
diseases is increasing. The identification of individuals at high risk of disease can 
trigger early intervention to reduce the risk of disease and its severity. In order for 
predictive tests to be accepted and used by those at risk, there is a need to 
understand people's perceptions of predictive testing. 
Method:  A meta-synthesis of qualitative research that explored patient and public 
perceptions of predictive testing for chronic inflammatory diseases was conducted. 
Studies were coded by researchers and patient research partners, and then 
organised into common themes associated with the acceptability or use of predictive 
testing.  
Results: Perceived barriers to predictive testing were identified including a concern 
about a lack of confidentiality around the use of risk information; a lack of motivation 
for change; poor communication of information; and a possible impact on emotional 
wellbeing. In order to reduce these barriers, the literature shows that a patient 
centred approach is required at each stage of the testing process. This includes the 
consideration of individual needs such as accessibility and building motivation for 
change; readily available and easy to understand pre- and post-test information; 
support for patients on how to deal with the implications of their results; and the 
development of condition specific lifestyle intervention programmes to facilitate 
sustainable lifestyle changes. 
Conclusion: Patients and members of the public had some concerns about predictive 
testing, however, a number of strategies to reduce barriers and increase 
acceptability are available. Further research is required to inform the development of 
a resource that supports the individual to make an informed decision about whether 
to engage in a predictive test, what test results mean, and how to access post-test 
support. 
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Background 
Chronic diseases with an inflammatory aetiology, such as inflammatory bowel 
disease (IBD), rheumatoid arthritis (RA), cardiovascular disease (CVD) and diabetes 
are typically characterised by dysregulation of the immune system and long-term 
activation of inflammatory processes. Over time, long-term inflammation can lead to 
damage in affected tissues (1). For many types of chronic inflammatory disease, 
early intervention has substantial benefits for the disease outcome (2,3), although 
help seeking and referral of patients after symptom onset are often delayed (4,5). 
 
Interest is emerging in the idea that treating people at risk of disease before 
symptoms appear can reduce the severity and consequences of future symptoms 
and may even reduce the risk of the disease developing (6,7,8). This has resulted in 
a drive to identify susceptibility markers in an attempt to identify individuals at risk of 
developing such diseases through predictive testing (i.e. genetic testing and non-
genetic risk assessments). For example, diagnostic and predictive genetic tests for 
maturity-onset diabetes of the young (MODY) are now available for many at risk 
families (9). Similarly, in RA, research is increasingly focusing on methods of 
identifying diagnostic biomarkers and disease mechanisms which predict the 
transition from health to RA (4,10,11,12).  
 
The availability of tests to predict the development of chronic inflammatory diseases 
is rapidly increasing, with a range of predictive tests available in various healthcare 
settings as well as directly available to the consumer from private companies in the 
form of home self-testing kits (13). Consequently the number of individuals at risk of 
developing a chronic inflammatory disease, who may be faced with the prospect of 
predictive testing, is increasing (14). The decision whether to engage in predictive 
testing may be driven by personal preferences for the management of risk and risk 
related information, understanding of risk and the meanings associated with being 
labelled as an ‘individual at risk’ (15).  
 
Previous qualitative research studies have been undertaken to explore perceptions 
of genetic risk in individuals at risk of developing certain illnesses, generating a 
broad range of themes and topics potentially important to consider before introducing 
new predictive testing. In particular, reviews of the qualitative literature have been 
undertaken within the field of cancer genetics where predictive testing is seen as 
important for the early detection and treatment of disease (16,17). This may, in part 
be driven by public perceptions about the severity of cancer and the need for early 
identification and intervention (18,19). Public perceptions of chronic inflammatory 
diseases such as RA, diabetes and CVD are more diverse (20,21,22), but often 
these diseases are thought to be less serious (22). Such beliefs might in turn 
negatively influence perceptions regarding the need for early detection and 
intervention for these diseases.   
 
Understanding people’s perceptions of predictive testing is paramount if these are to 
be accepted and utilised by those at risk. However, no review of the qualitative 
literature on public perceptions of predictive testing for common chronic inflammatory 
diseases has been undertaken to date.  The aim of the current study was therefore 
to identify research papers which have used qualitative methods to explore the 
perceptions of predictive testing held by members of the public and people at risk of 
developing chronic inflammatory non-malignant disease for which there are genetic 
and environmental risk factors.  Meta-synthesis methods were used to investigate 
common themes and implications for future predictive testing programmes.  
 
Methodology 
Meta-synthesis 
A literature search was performed using Medline/PubMed, PsycINFO, CINAHL and 
Google Scholar. Only peer-reviewed papers published between 1989 and 2014 were 
included and the search was limited to articles published in English. The search 
concentrated on articles looking at predictive testing and screening for chronic 
inflammatory disease, including diabetes, CVD, IBD, common inflammatory 
rheumatic diseases (RA, ankylosing spondylitis, Sjogren’s syndrome), asthma, 
multiple sclerosis and psoriasis. The search terms, inclusion criteria and the 
procedure for generation of the final sample of 11 articles presenting qualitative data 
relating to diabetes (n=7), CVD (n=3), and IBD (n=1) can be found in Figure 1. No 
relevant articles relating to any other disease were identified. 
 
To assess the quality of the identified papers KB and RS independently carried out 
quality appraisals, using an existing quality appraisal framework based on a modified 
version of the Critical Appraisal Skills Programme (23) qualitative checklist.  Each 
paper was rated using a three point scale (0 = Serious methodological issues; 1 = 
Minor methodological issues; 2 = Robust) for each of the following criteria 1) How 
relevant was the paper was to the present study’s research question? 2) To what 
extent did the paper add value to answering the research question? 3) How 
methodologically robust was the study?  
 
On the basis of these ratings each paper was then independently categorised as 
‘key’, ‘adequate and relevant’ or ‘flawed or not relevant’. There were no 
disagreements between researchers and none of the 11 papers identified were 
classed as ‘flawed or not relevant’. As a result all 11 papers were included in the 
meta-synthesis. 
 
Meta-synthesis: Data analysis and interpretation 
Meta-synthesis methods were used to identify interrelated themes from the 
published qualitative studies (24-26). The meta-synthesis focused on two 
substantive areas. The first was the major themes and findings related to the 
perception of testing to quantify the risk of developing a chronic inflammatory 
disease in a) family members of patients with the disease; b) patients with early 
symptoms; and c) the general population. The second focus was on the implications 
and recommendations for practice that are suggested by these findings.  
 
KB and RS independently read and analysed each of the selected articles. The data 
extracted from each paper were based on the original authors’ interpretation of the 
primary qualitative data. The themes derived from these primary data are termed first 
order constructs (27; Box 1). A thematic approach was then taken, grouping first 
order constructs from each paper into core themes. The researchers recorded which 
papers contributed to each theme, in terms of relevant data or contradictory or 
contrasting results.  KB and RS then discussed and agreed on emergent themes, 
and their relevance to the review’s primary aims.  The initial thematic framework was 
subsequently validated by a second round of coding of three of the 11 papers 
selected at random. This validation coding was conducted by three patient research 
partners with a chronic inflammatory disease (two EuroTEAM patient research 
partners with RA and one patient with RA from the University of Manchester RA 
Research User Group). Their feedback and recommendations supported the initial 
thematic framework and no substantial changes were made.  
 
Once the draft themes had been identified, the authors conducted a focus group with 
seven patient research partners (six RA patients and one patient relative recruited 
from the UK, Sweden, Estonia and Romania) in order to refine, prioritise and validate 
the themes. Two of these six individuals had also been involved in the initial 
validation coding of the data. During the 1.5 hour focus session the draft themes and 
corresponding quotes were presented and the following questions were discussed 
with the focus group members:  
 
1) Do these themes and subthemes look logical?  
2) Based on your experience as a patient or relative do these themes reflect reality? 
3) Do you think there are any important concepts described within these subthemes? 
4) Do you think that the overall themes or subthemes can be changed in anyway?  
5) Do you think that our meaning/interpretation of the quotes within the papers can 
be changed?  
6) What could be the implications of these findings for those at risk of developing a 
chronic illness in the future? 
 
The answers to these questions supported the themes presented by the researchers 
and highlighted the need to report clear recommendations for practice in this paper. 
These themes are termed second-order constructs as they are interpreted from the 
analysis of first order analysis of the primary data. These constructs were then 
interpreted and extended in the context of the wider research literature in an attempt 
to develop a conceptual framework (third order constructs; Box 1).  
  
Box 1: Synthesizing Qualitative Studies (27) 
First order constructs: The themes presented in papers identified by the literature search. 
These constructs are derived from the original authors’ interpretation of the primary 
qualitative data. 
Second order constructs: First order constructs from each paper are grouped into core 
themes to form second order constructs. These are presented in the results section of the 
present qualitative meta-synthesis. 
Third order constructs: Second order constructs are interpreted and extended in the 
context of the wider research literature in an attempt to develop a conceptual framework and 
recommendations for practice. 
 
 
Results 
Table 1 provides an overview of the participants in each stud, the methodological 
strategies and the quality appraisal score for each of the articles included in the 
meta-synthesis. Of the studies included in this metasynthesis all were conducted in 
either Europe (n=8) or the USA (n=3). The synthesis of themes is presented in three 
sections (Box 2). The first section describes five themes which represent patient and 
public perceptions of predictive testing to quantify risk of disease development. The 
second section describes four themes that explore recommendations for practice. 
Relevant quotes for each theme are included with details of the person providing the 
quote where available. The final section outlines the priorities of the patient partners 
derived from the focus group convened to discuss the themes. 
Box 2: Themes 
1. Perceptions of predictive testing 
1.1 The perceived value of testing to establish the risk of disease development  
1.2 Perceived barriers to predictive testing 
1.3 The use of test information to change behaviour and modify environmental risk  
1.4 Communication and understanding of  information regarding risk and genetic testing  
1.5 Impact of genetic testing and screening on emotional wellbeing 
2. Recommendations for practice 
2.1 Educating patients and their families about predictive testing 
2.2 Considering the most appropriate location for and method of the test 
2.3 Improving communication and the delivery of results 
2.4 Supporting patients to engage in health behaviours to reduce their risk 
3. The priorities of patient partners 
 
1. Perceptions of predictive testing  
The five themes related to the perceptions of predictive testing covered the 
perceived value of testing; the perceived barriers to testing; the use of risk 
information to change behaviour and modify environmental risk; the communication 
and understanding of information regarding risk and genetic testing; and the impact 
of genetic testing and screening on emotional wellbeing. 
 
1.1 The perceived value of testing to establish the risk of disease development  
Many ‘at risk’ individuals believed that predictive tests are reliable and effective at 
quantifying the risk of disease development (28). For diabetes, genetic predictive 
testing was thought to be more certain, factual and scientific than either non-genetic 
risk assessment (e.g. abnormal fasting glucose or obesity) or relying on an 
individual’s knowledge of their family history (28-30). 
 
You know it instantly [whether you’re at risk], by taking some blood. Do I have a 
predisposition, yes or no? Brief and effective; it’s [DNA test] a good test. (Female, 
53, No family history of diabetes; Page 1474, Netherlands (28)) 
 
On the other hand, some participants  thought that there was potential for health 
professionals to give false results (28), while others thought the advice on behaviour 
change and risk following screening was often contradictory and should therefore not 
be trusted (31). These participants clearly saw less value in the outcomes of 
predictive testing.   
 
I mean there are all sorts of tosh on television telling you should eat this, you 
should eat that, and then, you know, in a couple of years time, I mean they 
were banging on about eggs being bad for you and it all comes to light that 
you can eat as many eggs as you like … I mean I’m 59 this year and I think all 
throughout my time there has been this, there has been that and you think to 
yourself oh God I just want it to go away you know what I mean, leave you to 
your own devices. (Male, 59, high CVD risk; Page 4, UK (31)) 
 
If they want to prove that someone is at risk, they can manipulate the results. I 
don’t know how, since it’s quite new, quite precarious. (Female, 69, 
grandmother with diabetes; Page 1478, Netherlands(28))  
 1.2 Perceived barriers to predictive testing 
Participants identified a number of barriers to predictive testing. A common concern 
about testing related to the confidentiality of the information and the potential for 
results to be used by insurance companies and employers to discriminate against 
individuals (28,30,32,33).  There was a fear that testing may become obligatory and 
affect access to life or holiday insurance (33). Participants thought that this was 
particularly unfair as a high risk result from a test does not guarantee that you will 
develop the disease in question (32). In addition to being concerned about their data 
being shared with employers and insurers, some patients were concerned about 
receiving the results of a test via the post in case someone else opened the letter 
(34). 
 
The fact that you have predisposition for it, let’s say it’s in your genes, it 
doesn’t mean it has to be there so why should you be singled-out before you 
actually have it…. You know, why should I be turned down beforehand before 
it actually manifests itself? (IBD patient, age and gender not recorded;  Page 
498, USA (32)) 
 
Predictive testing was not seen as appropriate or relevant for all people. For 
example, personal traits such as age, heredity, lifestyle, and physical build were 
seen to influence the decision to take a genetic test for type 2 diabetes (33). 
Eastwood and colleagues (35) further reported that people from South Asian 
populations have a culture of using alternative therapies for  common ailments and 
the prevention of ailments. A GP is only visited when someone is ill and not as a 
preventative measure so individuals from such backgrounds may be less likely to 
access genetic tests.  In addition, in a study of South Asians, it was highlighted that 
family commitments might interfere with GP visits, predictive testing and other health 
promoting activities. 
 
There is a common saying that one should only visit a doctor if one is ill, 
otherwise doctors will put false doubts in one’s mind. That is an understanding 
of people. (South Asian female, 35, had CVD risk assessment; Page 469, UK 
(35)) 
 
 ... It’s probably the pace of life and the stress and if they’ve got children as 
well, that plays a big factor ... so I find that people tend to neglect their own 
health and lifestyle ... and sometimes I find with the Indian community, I mean 
they might have a father-in-law or a mother-in-law, and a lot of their time’s 
taken up with that ... so even if they did want to go to a keep-fit class or 
whatever, they might not be able to do it because of commitments. (South 
Asian female, 45, had CVD risk assessment; Page 469, UK (35)) 
 
Some people believed that predictive testing should be focussed on certain 
subgroups, suggesting for example that only people with increased risk, as 
determined by easily accessible clinical information, or early symptoms should be 
tested. Certain conditions such as diabetes were not perceived to be ‘severe’ 
enough to justify genetic predictive testing (28,36). 
 
I don’t think that people will think it concerns them. People will only respond to 
risk information when they have physical complaints and only then they will 
think “Now I have to be careful”. (Female, 65, mother with diabetes; Page 
1475, Netherlands (28)) 
 
Genetic testing is [more than for diabetes] for serious diseases like cystic 
fibrosis, cancer, kidney diseases. Having a family member with one of these 
diseases can be a reason to have a genetic test. (Female, 69, grandmother 
with diabetes; Page 1474, Netherlands (28)) 
 
Negative perceptions of the test itself, including inconvenience and discomfort were 
also cited in some of the studies (29,33). For example, the need to fast prior to the 
test, having blood taken, or attending an early appointment  would represent 
barriers, for some, to the uptake of predictive testing (33). Lengthy appointments and 
a long wait between tests meant that some participants in the study conducted by 
Adriaanse and colleagues (29) saw the process as burdensome.  
 
I can’t think there’s many people, erm, you know, who have got busy lives, 
who are gonna give up, er, 2 or 3 hours to go and have the test unless they 
feel ill. (Male, 40–49, did not attend CVD screening; Page 208, UK (33)) 
 
1.3 The use of test information to change behaviour and modify environmental 
risk  
Test results were perceived as empowering by several participants as they have the 
potential to motivate a person to make changes to their lifestyle to reduce their risk of 
ill health (32,35,37). A high risk result was seen to add a sense of urgency to engage 
in healthy behaviours which exceeded the impact of receiving information about 
familial risk (28,30).  
 
The DNA test gives the hardest “push” to live healthier. It will frighten me 
more than a test based on a family history, because it is the strongest 
evidence. (Male, 51, father and 2 brothers with diabetes; Page 1475, 
Netherlands (28)) 
 
Honey and colleagues (31) reported that a high level of commitment to behaviour 
change was achieved when the patient was shown how their risk score was 
calculated on a computer screen. By presenting the information in this way, 
participants could see how their risk would decline if they were to improve their 
lifestyle. 
 
That (risk score) has terrified me...and I will quit smoking. My intentions are to 
eat healthy, stop smoking altogether. (Male, 60, high CVD risk; Page 5, UK 
(31)) 
 
When considering how a low risk result is perceived, Markowitz and her colleagues 
(30) reported that some patients at risk of diabetes would continue to try and reduce 
their risk of developing the condition regardless of whether the test results were low 
or high. This suggests that a predictive test might have a positive impact on health 
behaviour irrespective of the result.  
 
Getting a ‘low’ genetic risk result would make me feel safer, but I would 
probably still do the exercise and the diet. (Patient at high phenotypic risk of 
type 2 Diabetes, age and gender not recorded; Page 571, USA (30)) 
 
On the other hand, for some participants, receiving a low risk result would probably 
result in a reduction in the level of motivation to engage with healthy behaviours (28).  
  
I can eat what I want, being fat is no problem, and being physically active, I 
prefer sitting behind the computer all day. (Female, 57, no family history of 
diabetes; Page 1476, Netherlands (28)) 
 
An individual’s pre-test motivation to lead a healthy lifestyle also influenced how they 
perceived their level of risk and their motivation to change their behaviour following 
the test result (30). For example, personal experiences with a chronic inflammatory 
disease, such as seeing a relative or friend suffer as a result of the condition, meant 
that an individual was more likely to change their lifestyle (28). Alternatively, if an 
individual had low motivation to engage in healthy activities prior to taking a (genetic) 
test, this might not necessarily change as a result of learning their test results; in 
some cases behavioural change would only follow the development of the relevant 
disease (31). Others would procrastinate, for example waiting for better weather or 
until after a special occasion (31). 
 
I’m not motivated ... I’m not afraid. I don’t think it’s at that point where I’ve got 
to, you know, “rally the troops and let’s get after it”. (Patient at high phenotypic 
risk of type 2 diabetes, age and gender not recorded; Page 570, USA (30)) 
 Rosedale  and colleagues’ (34) study raised the issue of participants’ choice related 
to knowing their risk of developing a chronic  disease such as diabetes. Some 
people do not want to know whether they are at risk, preferring not to have to 
engage with the results of the predictive testing and make lifestyle changes. For 
example, several people did not see the test results as a prompt to lower their 
cardiovascular risk because they believed death from a heart attack would be 
preferable to dying from a protracted illness or living into extreme old age (31). This 
group also resisted change because they believed that a short life of indulgence was 
better than a long life of denial. Those participants who believed that health 
outcomes are already predetermined or a matter of luck, were also less motivated to 
change (30,31). 
 
I know I am naughty because I quite like cream, you know, and things like that 
but I think gosh I am not going to be long on this mortal coil, I am not going to 
make myself miserable to the point of being really ultra miserable to maybe 
extend my lifespan by one or two years. (Male, 73, high CVD risk; Page 5, UK 
(31)) 
 
You can be as careful as you want; you can eat as healthily as you want; you 
can do all the exercise you want and you could still get ill. It is like J's mother 
who lived to be 101, smoked like a trooper, never had a cigarette out of her 
hand and she died of something silly. But you see it’s just jovial isn’t it? That is 
why I say it is just fate. You can do all the right things and still pick things up. 
(Male, 74, high CVD risk; Page 6, UK (31)) 
 1.4 Communication and understanding of  information regarding risk and 
genetic testing 
Some participants were unclear about the roles of environmental and hereditary 
factors in disease development and the integration of data relating to these variables 
into  predictive testing strategies (30). For example, Honey and colleagues (31) 
stated that one of their participants was sceptical about the accuracy of test results 
as they did not understand how the probabilities of disease were calculated.  
 
I don’t know whether bringing this data together into one score is a very 
realistic thing to do…there might be methodological problems...I don’t think 
you can add things like that together. (Male, 66, high CVD risk; Page 5, UK 
(31)) 
 
Participants invited to take part in actual screening programmes were not always 
aware of the reasons for their screening invitation and as a result some chose not to 
attend (30). 
 
I don’t know [why I was invited]. I thought diabetes had something to do with 
sugar, too, and . . . I’m not a sugar person. (Patient at high phenotypic risk of 
type 2 diabetes, age and gender not recorded; Page 570, USA (30)) 
 
Understanding of the actual test results also had an impact on health behaviour. 
Honey and colleagues (31) found that poor communication within the consultation 
can be a problem, as some high risk patients did not remember receiving a detailed 
explanation about their risk score or what it meant. Participants also reported 
confusion if they did not have any relatives with the condition, or knew little about the 
condition they were being tested for (29,32). Other people found positive test result 
difficult to conceptualise if they had no current symptoms (36). Without a real 
understanding of the test results, participants felt they were unable to make 
meaningful changes to their lifestyle. 
 
I have this piece of knowledge; it makes little or no difference to physically 
how I am. So how helpful is it, it’s not helpful is it in a way...  (Female, age not 
recorded, HCM gene positive (CVD); Page 90, UK (36)) 
 
1.5 Impact of genetic testing and screening on emotional wellbeing 
Most participants felt that testing for whether they were at risk of disease would not 
have a significant impact on their emotional wellbeing (26). For example, Adriaanse 
and colleagues (29) found that none of their participants were alarmed by their risk of 
type 2 diabetes as they believed that this was a manageable condition. Similarly, 
Wijdenes-Pijl and colleagues (28) found that genetic testing for diabetes caused very 
little or no psychological harm. Emotional impact was lowest when participants knew 
someone that was managing the condition well. Personal experience of a condition 
therefore influences how individuals respond to the results of a predictive test (9;37). 
 
If you’ve got diabetes and you, you listen to what people tell you, you can 
control that … I’m aware that diabetes in, in our current age, is quite treatable, 
hopefully, erm, so therefore, you know, even if I was diagnosed with diabetes, 
there’s ways and means that I could continue to live a normal life. (Male, 40–
49, did not attend CVD screening; Page 207, UK (33)) 
 
Familial risk information will not necessarily lead to worry [about disease risk], 
but it can raise awareness about the risk. (Female, 64, mother and brother 
with diabetes; Page 1476, Netherlands (28)) 
 
Some, participants also described how they believed that genetic predictive testing 
can in fact reduce anxiety (9). Participants who believed they were at a high risk due 
to hereditary factors describe a substantial relief and a feeling of safety when they 
received a low risk result (30). Many of those who perceived themselves to be at a 
low risk chose to take the test with the expectation of getting a ‘negative’ result so 
they did not have to worry about getting the condition. Genetic testing was therefore 
seen as a way to put their mind at rest (36). 
 
I’d want to know whatever. You’re better knowing and then you can plan, or at 
least get it straight in your mind, and then once it comes along you’re ready 
for it, instead of really worrying. I mean it’s always worse not knowing. (Middle 
aged white male with diabetes, father of a child at risk of diabetes; Page 249, 
UK (9)) 
 
However, Ormondroyd and colleagues (36) have warned that health professionals 
need to manage the expectations of those undergoing testing, as some people in 
their study who had thought they were low risk were shocked by how they felt when 
they received a high risk result. Others reported that a positive result led to stress 
among patients and family members, especially if the person was otherwise 
asymptomatic (32).  
 
Really and truly, I was absolutely horrified when it came back and said that I 
had it. I mean I really was horrified... It was a dreadful shock (Female, age not 
recorded, HCM gene positive (CVD); Page 90, UK (36))  
 
Some participants were not comfortable with the uncertainty associated with 
predictive test results for multifactorial diseases, and the potential for unnecessary 
anxiety and behavioural change (35,36). 
 
You see, as far as I’m concerned, it’s actually become a bit of a nuisance 
really, unless they, until they can tighten it down to a specific thing. I didn’t 
realise how wide, just because you have it doesn’t mean you’re going to get it 
and that’s the problem isn’t it? (Female, age not recorded, HCM gene positive 
(CVD); Page 90, UK (36))  
 
A stepwise approach, for example where participants visit their health professional 
three times to complete a genetic test for diabetes, could be effective at reducing 
anxiety for those undergoing predictive testing. Participants in the study conducted 
by Eborall and colleagues (37) perceived initial tests to be routine and rarely 
expected to receive a high risk result. Having three tests also allowed the 
participants to prepare for the results and build a rapport with the health 
professionals. 
 
So I go for number one, I go for number two and then I have to go to number 
three. So it’s a build up all the time, making me think, well OK there’s a 
possibility you know . . . there’s a strong possibility you know’ in that sense 
[...] you’ve gone through the three, so your brain’s adjusted anyway. (Female, 
64, impaired glucose tolerance (predictive testing  for diabetes); Page 3, UK 
(37)) 
 
When considering the impact of testing on personal relationships, a number of 
positive outcomes were highlighted. For example, Wijdenes-Pijl and colleagues (28) 
found that participants felt that a high risk result acted as a facilitator to prompt 
discussions within the family, encouraging the development of a support network for 
those who are affected. Families also benefit when a low risk result was given as this 
helped to reduce anxiety within a family about the participant’s health. The 
predominant motivation for coming forward for pre-symptomatic testing was the 
‘need to know’ (36). 
 
I think that when you’re aware of diabetes running in your family, it can help to 
talk about it with each other. I notice that the relationships in our family are not 
distorted. We talk about it [diabetes in the family] with each other. Not that we 
get anxious about it, but more to be supportive for other family members. It’s 
no longer a taboo. (Female, 47, no family history of diabetes; Page 1477, 
Netherlands (28))  
 
Well I suppose it’s better knowing if you’ve got something, if it’s treatable...it 
was a sort of joint decision really I said yes I’d go but mum and dad said 
you’re going anyway, so I didn’t get much choice in it which is fair enough. 
(Male, age not recorded, HCM gene positive (CVD); Page 90, UK (36)) 
 
However, the potential for a negative impact on family relationships was also 
highlighted. Some participants were concerned that a positive test result may cause 
people to worry about the health of their children (28). Sharing results was also an 
issue if other family members did not want to know that they may be at risk. Finally 
there was the concern that someone with a high risk of developing a chronic disease 
may be blamed for the potential risk for other family members (28). 
 
My relatives will get anxious [if our family history is assessed]. [...] There are 
some who would rather not know that. So, I think that it can cause anxiety for 
some people. (Female, 57, no family history of diabetes; Page 1477, 
Netherlands (28)) 
 
2. Recommendations for practice 
Four themes were identified that related to recommendations for practice. These 
were: educating patients and their families about predictive testing; considering the 
most appropriate location for and method of the test; improving communication and 
delivery of results; and lastly supporting patients to engage in healthy behaviours to 
reduce their risk.  
 
2.1 Educating patients and their families about predictive testing 
Many members of the public lack the knowledge and understanding of (genetic) 
predictive testing that is necessary to be able to make an informed decision about 
whether to take part in such testing and engage with test results (9,28,34,36). It is 
therefore important for individuals to receive intelligible pre-test information on the 
condition they are being tested for (34). The information should cover the risks and 
benefits of the test, technical aspects of testing, the implications of their results for 
themselves and family members, treatment options, referral information, post-test 
counselling and support groups (32,34). Individuals should also be made aware of 
the risk factors that led to their screening invitation in the first place (37). For 
example, when this information was provided before a genetic test for IBD (32), 
participants reported a reduction in fear and anxiety about testing and an increase in 
understanding of the test results.  
 
I thought I’d be more upset about it, but I didn’t seem upset. I think because 
we’ve spoken so much to everyone about it that we knew that’s what we 
wanted to do. (Mother of child at risk of diabetes; Page 254, UK (9)) 
 
Health professionals should also focus on motivation for testing and how the 
participant perceives the condition and the testing process (9). This discussion will 
also highlight any misconceptions about genetics and inheritance which should be 
addressed as well as increasing confidence in the results of genetic tests (9) and 
other forms of predictive testing.  
 
2.2 Considering the most appropriate location for and method of the test 
Eastwood and colleagues (35) report  that certain patient groups are more likely to 
engage in testing if it is conducted outside of primary or secondary care. For 
example, South Asian populations were found to benefit from CVD screening in 
religious and community settings rather than at their GP practice. These locations 
offered increased accessibility and the community reported a positive perception of 
the test if the health professionals were organised in their approach and gained the 
support of a respected community member (35).  
 
We’re screening between sixty to eighty people [in a single session] and if 
we’re not organised it’s difficult. So the first thing we did was identify someone 
in the temple who will take that responsibility. We will be seen as outsiders 
going in and imposing restrictions. So we have Dr X, who is a good organiser 
from the temple who is seen as a senior in the temple... along with the clinical 
lead from the temple for this project who is Dr Y. (Clinical staff involved in 
CVD risk assessment, age and gender not recorded; Page 469, UK (35)) 
 
An American study by Rosedale and colleagues (34) found that diabetes screening  
in a dental setting encouraged patients, who would normally not have considered 
testing, to take part. Collecting oral blood during a routine dental examination was 
preferred to drawing blood from the finger as would be carried out in more traditional 
testing. The researchers observed that:   
 
The screening approach wasn’t intimidating to the patient and actually was 
very pleasant... according to most of the patients. Most of the patients were 
used to sitting in the dental chair and getting a cleaning, so the collection of 
oral blood wasn’t a problem. Many patients stated how much they hated finger 
sticks because of the pain and this made potential subjects hesitant to 
participate. (Page 285, USA (34)) 
 Some participants further remarked that it was easier to talk with staff at the dental 
practice, rather than other medical professionals. Education about diabetic risk 
provided in the dental office was therefore invaluable. Participants further reported 
that the location was convenient, would encourage more regular testing and that 
they would be happy to be tested for other conditions. 
 
Today, I have time and am relaxed. I go to the doctor maybe once a year for a 
routine check but why wait? (Participant diabetes screening at dentist, age 
and gender not recorded; Page 284, USA (34)) 
 
2.3 Improving communication and the delivery of results 
The manner in which information about their screening result is conveyed to 
participants is key to their understanding of the results and their implications (28,31). 
Honey and colleagues (31) found that for most participants it was acceptable to be  
informed about their cardiovascular risk status in person or by telephone, whereas 
receiving test results in a letter caused confusion for some participants as they were 
unable to ask questions.  
 
I got a letter from the doctor’s saying “as you are at a high risk of a stroke or heart 
attack”...well I nearly died, and I thought ‘well what have my results come up as? 
(Male, 66, High CVD risk; Page 3, UK (31)) 
 
Honey and colleagues (31) argue that the communication style of health 
professionals can also play a role in the level of motivation for behaviour change. 
Participants were less motivated when the health care professional was seen to 
‘downplay’ a high risk score by using phrases such as, ‘it is only slightly higher’, or 
make light of the risk by using humour. It is therefore important that the level of risk is 
accurately communicated to the patient. The person who delivers a test result also 
appears to have an impact on the person’s understanding of these results and their 
level of motivation for behaviour change (31). Lewis and colleagues (32) reported 
that several respondents indicated that they would prefer to receive pre and post-test 
information from a specialist rather than their GP. 
 
They [specialists] are probably more in tune to different markers, symptoms 
than maybe just a regular primary care physician would be. (Unaffected first-
degree relative of IBD patient, age and gender not recorded; Page 498, USA 
(32)) 
 
I think if the results are positive that they did have the disease, they are more 
susceptible to it, then the GI specialist, of course, should give the results.  
(IBD patient, age and gender not recorded; Page 498, USA (32)) 
 
Some members of the public also believed that they should not have the 
responsibility of telling family members about possible risk (36). They felt that this 
should be done by health professionals who could also explain the risk and options 
for genetic testing. 
 
I think it isn’t perhaps something that should be left to the family to 
communicate because we all have our own perceptions as to whether X or Y 
is healthy or needs to have a test. How on earth do we know, when we are 
not qualified to make that decision. (Female, age not recorded, HCM gene 
positive (CVD); Page 91, UK (36)) 
 
2.4 Supporting patients to engage in health behaviours to reduce their risk 
A study by Markowitz and colleagues (30) suggested that testing for type 2 diabetes 
should be individualised and based on each patient’s risk perception and current 
level of motivation to engage in health behaviours to prevent diabetes. By 
considering current levels of motivation, the health professional can work with the 
patient to promote or maintain lifestyle changes when faced with a low or high risk 
result. It is also important for the health professional to consider how they can 
convey enough information about the potential consequences of the disease to 
justify lifestyle change, without raising anxiety to such an extent that it causes 
disengagement (28).To optimise motivation, the decision to undertake a predictive 
test should be linked with the opportunity to enrol in a lifestyle intervention 
programme to provide structure, education and support to facilitate sustainable 
lifestyle changes (30). 
 
3. The priorities of patient partners 
When considering the literature, patient partners believed that the greatest barrier to 
genetic testing for chronic inflammatory diseases was a current lack of knowledge 
about the need for testing (9,28,34). Patient partners agreed that a staged approach 
was required, starting before the test was administered with clear, succinct and easy 
to read information about the condition, and the reasons for testing (31,37). The 
focus group highlighted the need for health professionals to take the time to explain 
the meaning of risk information, clearly stating what percentage or figure represents 
a ‘high risk’. A written summary of the results for the patient to take away also aids 
understanding and communication with family members (31).  
 
An additional consultation to discuss possible lifestyle intervention programmes and 
the impact of these results on family members was also seen as good practice (30). 
The patient partners suggested that this session could be run by a psychologist who 
had skills in motivating behaviour change. This follow up care was seen as a priority 
in order to manage the emotional impact of the result. 
 
 
Discussion 
The current meta-synthesis of the qualitative literature highlights that predictive 
testing can be viewed by those at risk of developing chronic inflammatory disease as 
a reliable way to ease concerns about the risk of developing a condition, or gain 
valuable information to motivate behaviour change (28). However, a number of 
papers discuss a lack of understanding about the type of information that a predictive 
test can provide, what that information means in terms of level of risk and how to 
reduce that risk (28,31,37). These perceptions may have a negative impact on how 
predictive testing for chronic inflammatory disease is viewed and utilised by those at 
risk.  
 
In order to reduce the barriers to the uptake to predictive testing, the literature 
suggests that a patient centred approach is required at each stage of the process. 
This can be achieved in the following ways. Firstly, there is a need for readily 
available and easy to understand pre-test information (34). This should include 
information on genetics and inheritance, and address current concerns that the 
results of predictive tests are inaccurate, lack meaning or are not confidential 
(28,30,32,33).  Further research is required to work with patients and members of 
the public to design an informational resource that describes technical aspects of 
testing, what a predictive test can tell you and how the results will be used. This will 
support the individual to make an informed decision about whether to engage in a 
predictive test (9,28,34,36).  Information is also required about the condition the 
individual is being tested for, and the risks and benefits of a predictive test for that 
condition. For example, Wijdenes-Pijl et al. (28) found that people with first-hand 
experience of a condition are more likely to engage with predictive testing; therefore 
a resource such as a short film may increase understanding of the potential benefits 
of a predictive test and early intervention.  
 
Perceptions of predictive testing become more positive when health professionals 
tailor their approach to specific groups (37). A number of variables were found to 
impact on an individual’s decision to engage in genetic testing including age, 
ethnicity, current lifestyle, individual differences in the level of motivation for change 
and level of anxiety (33). Accessibility can be improved by taking predictive tests into 
the community (35), while a stepwise approach, where participants visit their health 
professional a number of times, has also been found to be effective at reducing 
anxiety (37). Further research is needed to explore the needs of different groups to 
understand the potential barriers to accessing predictive tests.  
 
Once an individual has engaged with a predictive test, the health professional can 
work to maximise the impact of the test results by discussing what the level of risk 
means (31). Health professionals can also offer support to patients on how to deal 
with the implications of their results for themselves and their family. This may include 
developing a resource that provides further information on referrals, post-test 
counselling and support groups (32,34).  
 
Finally, when considering the long-term impact of a predictive test, it is important to 
address questions about if and how risk would decline if an individual were to 
improve their lifestyle (31). Where appropriate the development of condition specific 
lifestyle intervention programmes would provide structure, education and support to 
facilitate sustainable lifestyle changes (30). By considering current levels of 
motivation, the health professional can also work with the patient to promote or 
maintain lifestyle changes when faced with a low or high risk result. Once again, 
further research is required to explore the potential barriers to implementing change 
to manage risk among different groups. 
 
Comparisons with existing literature 
Qualitative studies on the perceptions of predictive testing have been undertaken in 
the field of cancer (17). Similarities between this condition and chronic inflammatory 
diseases include the need for health professionals to facilitate family communication 
when an individual is faced with a high risk result (16,17, 28). Tensions can arise 
when informing family members about their practical risk, and there is little guidance 
on how this information should be shared (16). Heshka and colleagues (17) also 
found that genetic testing had little effect on behaviour, and did not change 
perceived risk of cancer. This highlights the importance of the development of pre 
and post-test patient education strategies as recommended in the current meta-
synthesis. Our paper also identified recommendations for practice that have not 
been presented in the cancer literature. These include the idea that patient groups 
are more likely to engage in testing if it is conducted outside of primary or secondary 
care, and the promotion of a lifestyle intervention programme to motivate patients to 
change their behaviour and reduce risk. However, there are limitations when drawing 
comparisons between the chronic inflammatory diseases reviewed here and the 
findings of cancer studies as those at risk of cancer may have greater knowledge 
and more complete prototypical beliefs. Furthermore perceptions of severity are 
usually more severe in the context of cancer (18,19,28). 
 
Limitations 
The aim of this meta-synthesis was to systematically describe the perceptions of 
genetic testing for chronic diseases of inflammatory origin in the general public and 
make recommendations for the development of future predictive tests. The review 
procedure only found studies from developed countries (UK, USA and the 
Netherlands) that explored genetic testing for diabetes, cardiovascular disease and 
inflammatory bowel disease, and our findings may not be generalizable to other 
cultures.  
 
It is interesting to note that our search strategy failed to identify any studies that 
explored the views of predictive testing among patients with a range of common  
chronic inflammatory diseases in particular the chronic inflammatory rheumatic 
disease (RA, ankylosing spondylitis, SLE and Sjogren’s syndrome), psoriasis and 
MS, despite ongoing work to quantify disease risk in individuals  from high risk 
populations (38). The patient research partners highlighted that RA has a number of 
unique features when compared to the diseases which the studies captured in this 
meta-synthesis focussed on. For example, deformity and chronic pain are not 
typically associated with diabetes and coronary heart disease. Furthermore an 
evidence base does not yet exist for the primary or secondary prevention of RA even 
if an individual is identified as being at high risk (although a number of intervention 
studies are ongoing in this field).  Such disease specific features may influence an 
individual’s decision as to whether or not to undergo a predictive test. Further 
research is needed to explore variations in perceptions of predictive testing across 
different disease contexts in order to develop to recommendations for practice that 
are specific to each condition. This meta-synthesis has also grouped different 
predictive tests together. Future work should compare the views of at risk subjects 
on different types of tests. 
 
The authors focused on peer reviewed, published papers only. The grey literature 
was therefore not included. It is possible that there are other relevant studies that 
were not identified by our search strategy. 
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Table 1. Characteristics of papers included in the meta-synthesis 
Paper 
(Diabetes) 
Participants  Country  Primary objectives Methods and 
analysis 
Type of test used Score 
Adriaanse et 
al., 2002 (29) 
20 type 2 diabetes 
patients (10 male, 10 
female). 
20  persons at increased 
risk of diabetes (10 male, 
10 female).  
NL Explore the psychological 
impact of a stepwise 
population-screening 
project for Type 2 diabetes 
Methods: semi 
structured 
interviews  
Analysis: 
content 
analysis 
Symptom Risk 
Questionnaire 
Various glucose 
screening tests 
2-1-1 
Eborall et al., 
2012 (33) 
13 persons without a 
diabetes diagnosis who 
attended a diabetes 
screening  
11 persons without a 
diabetes diagnosis who 
did not attend the 
UK Explore the perceptions of 
those invited to attend the 
MY-WAIST screening 
study for type 2 diabetes 
(i.e. explanations for (non) 
attendance; views on the 
specific screening 
Methods: 
semi-structured 
interviews 
Analysis: 
constant 
comparative 
method 
Oral glucose 
tolerance screening 
test  
2-2-2 
screening (gender 
breakdown not provided). 
strategy). 
Eborall et al., 
2014 (37) 
23 persons without 
diagnosis of diabetes 
attending type 2 diabetes 
screening process (14 
male, 9 female). 
UK 1. Provide insight into 
factors that contribute 
might contribute to anxiety 
as a result of screening 
2. To explore expectations 
of and reactions to the 
screening experience of 
patients with positive, 
negative, and intermediate 
results. 
Methods: 
prospective 
qualitative 
interview  
Analysis: 
Thematic 
analysis. 
Various glucose 
screening tests 
 
 
2-2-2 
Markowitz et 
al., 2011 (30) 
22 overweight 
participants at high 
phenotypic risk for type 2 
diabetes (13 male, 9 
USA 1. Explore perceptions of 
diabetes genetic risk 
testing compared to risk 
testing using non-genetic 
Methods: 
semi-structured 
interviews using 
hypothetical 
Genetic test 
& non-genetic risk 
factors 
2-2-2 
female). risk factors  
2. To explore the impact of 
test results on motivation 
for behaviour change. 
scenarios. 
Analysis: 
thematic 
analysis 
Rosedale et 
al., 2012 (34) 
9 diabetes patients 
(gender breakdown not 
provided). 
USA Explore patient 
experiences of diabetes 
screening during 
periodontal visit (e.g. 
thoughts about 
combination with dental 
visit; preferences 
regarding FSB glucose 
testing compared with 
GCB glucose testing) 
Methods: semi 
structured 
Interviews  
Analysis: 
constant 
comparative 
analysis 
Blood glucose test 2-2-2 
Shepherd et 
al., 2000 (9) 
4 family members of 
young person at risk of  
UK To explore the perceptions 
genetic testing of  a family 
Methods: 
Open-ended 
Genetic test 2-1-1 
MODY (1 male, 3 
female). 
6 health specialists 
(consultant, geneticist, 
genetics nurse specialist, 
diabetologist, 
paediatrician, paediatric 
specialist nurse.  Gender 
breakdown not provided). 
affected by MODY and the 
healthcare professionals 
involved 
 
 
qualitative 
interviews prior 
and post 
genetic test 
Analysis: 
Content 
analysis 
Wijdenes-Pijl 
et al., 2011 
(28) 
27 persons with a family 
history of diabetes 
18 persons without a 
family history (11 male, 
34 female). 
NL Explore perceptions of 
predictive testing based on 
DNA test results and 
family history assessment. 
Methods: 
Focus groups 
Analysis: 
thematic 
analysis 
Genetic test and 
family history 
assessment 
2-2-2 
Paper  
(CVD) 
Participants  Country  Primary objectives Methods and 
analysis 
Type of test used Score 
Eastwood et 
al., 2013 (35) 
12 persons at risk of 
CVD (6 male, 6 female). 
12 health professionals 
involved in risk 
assessments (9 male, 3 
female). 
 
UK Explore the feasibility and 
potential impact of CVD 
risk assessment targeting 
South Asian groups  
Methods: 
semi-structured 
interviews 
Analysis: 
thematic 
framework 
analysis 
NHS Health Check 
(anthropometrics, 
blood pressure, 
cholesterol 
and glucose testing, 
lifestyle assessment, 
tailored advice) 
2-2-1 
Honey et al., 
2014 (31) 
37 patients at a high 
10-year risk of a 
cardiovascular event (30 
male, 7 female). 
UK Explore the perceptions of 
patients identified as being 
at ‘high risk’ of 
cardiovascular events, with 
particular reference to the 
potential responses to risk 
messages. 
Methods: semi 
structured 
interview 
Analysis: 
Thematic 
analysis 
NHS health check 
(calculates individual 
risk by physical 
assessment and 
questions 
about medical 
history, family history 
and lifestyle) 
2-2-2 
Ormondroyd 22 persons eligible for UK Explore perceptions of the Methods: Semi Genetic test 2-2-2 
et al., 2014 
(36) 
pre-symptomatic genetic 
testing for Hypertrophic 
Cardiomyopathy or Long 
QT syndrome (9 male, 
13 female). 
cascade testing process, 
impact of pre-symptomatic 
genetic testing and 
attitudes towards direct 
contact as an alternative to 
family-mediated 
dissemination for inherited 
cardiac conditions. 
structured 
interviews. 
Analysis: 
thematic 
analysis 
Paper 
(IBD) 
Participants  Country  Primary objectives Methods and 
analysis 
Type of test used Score 
Lewis et al., 
2009 (32) 
30 IBD patients (14 male, 
16 female). 
18 unaffected first-
degree family members 
/spouses (6 male, 12 
female). 
USA Explore the perceptions, 
preferences, knowledge 
and needs surrounding 
genetic testing for IBD 
Methods: focus 
groups  
Analysis: 
thematic 
analysis 
Genetic test 2-2-2 
Please note: Score refers to the quality appraisal of the papers carried out prior to the meta-synthesis
 
